Investors / United States / NYBC Ventures
NYBC Ventures
Corporate VC · Boston, MA, United States · North America
NYBC Ventures is a venture fund launched by New York Blood Center Enterprises with a $50M commitment. It invests in blood and cellular therapies and related technologies, supporting therapeutics and devices.
Invests inHealthcare & Biotech
In its own wordshematologytransfusion medicinecell therapyinfectious diseasetherapeuticsmedical devices
Your fit with NYBC Ventures
Four questions about your startup
See how your round matches what it backs, point by point.
Or find every investor that fitsNYBC Ventures lists 11 checked portfolio companies on its own site and is named in 3 funding rounds. Its most frequent entry is Series A, 33% of the companies with a known first round. Its largest theme is Healthcare & Biotech (100%). 67% of its companies are based in United States. It invests most often alongside Michigan Capital Network, Sofinnova and AN Venture Partners.
Counts come from funding rounds that name NYBC Ventures, complete from mid-2025: earlier rounds appear only when they were reported later. Round amounts and full round histories are on Fundup AI.
Round figures show recent activity, not NYBC Ventures' whole history. Rounds on record name 3 companies; its own site lists 11. Funding rounds are complete from mid-2025, so counts and the yearly trend undercount a firm that invested before then. The portfolio, themes and places come from its own site and are not affected.
Entry stage
share of companies by the stage of its first roundShow as a table
| Value | |
|---|---|
| Pre-seed | 0% |
| Seed | 0% |
| Series A | 33% |
| Series B | 33% |
| Growth | 33% |
Activity by year
rounds it joined, last 10 yearsShow as a table
| Total | Rounds it led | |
|---|---|---|
| '17 | 0 | 0 |
| '18 | 0 | 0 |
| '19 | 0 | 0 |
| '20 | 0 | 0 |
| '21 | 0 | 0 |
| '22 | 0 | 0 |
| '23 | 0 | 0 |
| '24 | 0 | 0 |
| '25 | 1 | 0 |
| '26 | 2 | 0 |
Investor profile
percentile among all firmsShow as a table
| Measure | Percentile of all firms | Value |
|---|---|---|
| Portfolio size | 27th | 11 companies |
| Recent activity | 76th | 3 rounds in 12 months |
| Early stage | 54th | 0% of entries at pre-seed or seed |
| Evidence | 75th | 9% of companies confirmed by a round |
| Sector focus | 100th | 100% in its largest sector |
| Reach | 58th | 3 countries |
Invests most often with
firms sharing its portfolio companiesShow as a table
| Share | |
|---|---|
| Michigan Capital Network | 2 |
| Sofinnova | 2 |
| AN Venture Partners | 1 |
| ARCH Venture Partners | 1 |
| Agent Capital | 1 |
| Alix Ventures | 1 |
| Altitude Life Science Ventures | 1 |
| Arboretum Ventures | 1 |
Its portfolio companies
where they are based, and what their own sites showSite status
- Site answers11100%
- No longer answers00%
- Points to another company00%
- Parked or sold domain00%
A site that stops answering three checks in a row is counted as no longer answering; that is not proof of closure. A site that points to another company is often an acquisition.
Investment themes
share of its checked companiesThis firmAll checked companies
Show as a table
| This firm | All checked companies | |
|---|---|---|
| Healthcare & Biotech | 100% | 15% |
Co-investor network
who it backs companies with, and who they back togetherAll co-investors or Compare portfolios with Michigan Capital Network
Compare NYBC Ventures head to head
portfolio size, rounds, entry stages, themes and the companies both backThree or more firms at once: portfolio overlap.
Recent portfolio activity
when companies last raised with NYBC Ventures| Date | Company | Stage |
|---|---|---|
| 23 Oct 2026 | Series C+ | |
| 8 Jun 2026 | Series B | |
| 9 Dec 2025 | Series A |
Round details for NYBC Ventures
Amounts, full round histories and every co-investor in NYBC Ventures' rounds are on Fundup AI. VCinfo covers investors and their portfolios.
Portfolio
11 companies checked against their own sites| Company | What it does | Themes | First round with it | Evidence |
|---|---|---|---|---|
| Akadeum Life Sciences develops and provides cell separation technology for therapeutic applications | Healthcare & Biotech | Portfolio page | ||
| Aronora is reimagining cardio-hematology to leave no patient behind by developing medicines for thrombolytic intervention and management of life-threatening risk for thrombosis | Healthcare & Biotech | Portfolio page | ||
| Avencell develops next generation immunotherapies for hard-to-treat cancers | Healthcare & Biotech | Portfolio page | ||
| The company develops and provides an automated cell therapy manufacturing platform | Healthcare & Biotech | Dec 2025Series A | Funding round | |
| City Therapeutics is a clinical-stage biotechnology company developing the next generation of RNAi therapeutics designed to silence the expression of disease-relevant proteins | Healthcare & Biotech | Jun 2026Series B | Page + round | |
| The company provides growth capital to companies transforming healthcare | Healthcare & Biotech | Portfolio page | ||
| Immusoft engineers B cells as biofactories for therapeutic protein delivery | Healthcare & Biotech | Portfolio page | ||
| KaloCyte is developing ErythroMer, a dried, bio-inspired artificial red blood cell, to treat life-threatening blood loss when stored red blood cells are unavailable, undesirable or in short supply. | Healthcare & Biotech | Portfolio page | ||
| STAR Therapeutics discovers and develops antibody therapies for patients with serious diseases | Healthcare & Biotech | Oct 2026Series C+ | Funding round | |
| STRM.BIO is developing a platform for in vivo gene therapy delivery using megakaryocyte-derived extracellular vesicles | Healthcare & Biotech | Portfolio page | ||
| Vitestro advances blood draw automation with clinical validation, expert engineering, and close collaboration with leading hospitals. | Healthcare & Biotech | Portfolio page |
About this data
site last read 5 Nov 2026- Site
- nybcventures.com
- Last read
- 5 Nov 2026
- Watching since
- 5 Nov 2026
- Rounds since
- 9 Dec 2025
- Companies checked
- 11
Rates come from what VCinfo has observed since observation_start. Firms tend to remove companies that closed, so early rates understate reality. A company leaving a portfolio page does not mean it closed or exited. An unreachable site means our checks failed, nothing more.
Get NYBC Ventures' profile as data
Pull NYBC Ventures' portfolio, co-investors and changes through one API key or MCP, open every portfolio row, compare it with other firms, and get an email when it adds a company or files a fund.
Work email, sign-in link by email. Already have an account? Log in- Ask AI5 plain-English investor searches a day
- Full listsEvery portfolio row and two-firm overlap
- API and MCP100 REST or MCP calls a month, one key
- AlertsFollow 5 investors for portfolio and fund changes
$ curl -H "X-API-Key: YOUR_KEY" \
https://api.vcinfo.io/v1/firms/nybcventures.com
# also
GET /v1/firms/nybcventures.com/portfolio
GET /v1/firms/nybcventures.com/coinvestors
GET /v1/firms/nybcventures.com/news